Literature DB >> 9663723

Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study.

F Bazzoli1, M Zagari, P Pozzato, O Varoli, S Fossi, L Ricciardiello, G Alampi, G Nicolini, S Sottili, P Simoni, A Roda, E Roda.   

Abstract

BACKGROUND: Studies demonstrating the efficacy of short-term low-dose triple therapies including omeprazole (O), clarithromycin (C) and a nitroimidazole (tinidazole, T) for Helicobacter pylori eradication have largely been open and uncontrolled, and have not assessed antibiotic sensitivity. Simpler regimens using the component drugs have not been evaluated. AIM: To evaluate the OCT regimen in a randomized, controlled trial, testing for pre- and post-treatment antibiotic resistance and comparing, in a factorial design, the OCT regimen with simpler combinations of its components.
METHODS: One hundred and twenty-eight patients (68 males, 60 females, age 22-80 years, mean 53 years) with H. pylori gastritis were randomly assigned to one of the following four treatment groups: (C) clarithromycin 250 mg b.d.; (OC) omeprazole 20 mg o.d. + clarithromycin 250 mg b.d.; (CT) clarithromycin 250 mg b.d. + tinidazole 500 mg b.d.; (OCT) omeprazole 20 mg q.d.s. + clarithromycin 250 mg b.d. + tinidazole 500 mg b.d. The drugs were administered for 1 week. Medical interview, upper gastrointestinal endoscopy (with four antral and four corpus biopsies) and the 13C-urea breath test were carried out for all patients prior to and 4 weeks after treatment. Biopsy specimens were used for the urease test, histology, and culture and sensitivities.
RESULTS: All but one patient completed treatment. Side-effects were rare and mild in all groups. The eradication rate was 93.8% in group OCT, 59.4% in group CT, 31.3% in group OC and 6.3% in group C. Pre-treatment metronidazole resistance was 12.8%, clarithromycin 1.1% and, to both antibiotics, 2.1%. In patients with pre-treatment metronidazole resistance, the eradication rate was 75% in group OCT and 33% in group CT. Post-treatment resistance to clarithromycin was induced in 28.5% of the failures in group C, but in none of group OC. Resistance to both antibiotics occurred in 22.2% of the failures in group CT and in none of group OCT.
CONCLUSIONS: (i) The high efficacy of the OCT regimen is proved and each of the individual components of the regimen is essential to the result, possibly via a synergistic effect. (ii) Pre-treatment metronidazole resistance is scarcely relevant to the outcome. (iii) Acquired resistance is essentially nil if omeprazole is part of the regimen.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663723     DOI: 10.1046/j.1365-2036.1998.00330.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

Review 2.  Treatment after failure: the problem of "non-responders".

Authors:  J Q Huang; R H Hunt
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

3.  Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.

Authors:  Rocco Maurizio Zagari; Gabriele Bianchi-Porro; Roberto Fiocca; Giovanni Gasbarrini; Enrico Roda; Franco Bazzoli
Journal:  Gut       Date:  2006-10-06       Impact factor: 23.059

4.  Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection.

Authors:  Josip Bago; Anita Galović; Zeljka Belosić Halle; A Bilić; M Bevanda; Petra Bago
Journal:  Wien Klin Wochenschr       Date:  2004-07-31       Impact factor: 1.704

5.  Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.

Authors:  Josip Bago; Branko Pevec; Monika Tomić; Marinko Marusić; Vinko Bakula; Petra Bago
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 6.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

7.  Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile.

Authors:  Arnoldo Riquelme; Alejandro Soza; Cesar Pedreros; Andrea Bustamante; Felipe Valenzuela; Francisco Otarola; Eduardo Abbott; Marco Arellano; Brenda Medina; Alejandro Pattillo; Douglas Greig; Marco Arrese; Antonio Rollan
Journal:  World J Gastroenterol       Date:  2007-06-07       Impact factor: 5.742

8.  Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.

Authors:  Engin Altintas; Orhan Sezgin; Oguz Ulu; Ozlem Aydin; Handan Camdeviren
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

9.  Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice.

Authors:  P J Jenks; A Labigne; R L Ferrero
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

10.  Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Helicobacter pylori Infections: An In Situ Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study.

Authors:  Jewel Ju Ea Kim; Ildikó Kocsmár; György Miklós Buzás; Ildikó Szirtes; Orsolya Rusz; Csaba Diczházi; Attila Szijártó; István Hritz; Zsuzsa Schaff; András Kiss; Éva Kocsmár; Gábor Lotz
Journal:  Pathol Oncol Res       Date:  2021-06-29       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.